Epoetin alfa– Biosimilar Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Epoetin alfa– Biosimilar 2022,” report provides comprehensive insights about 15+ companies and 20+ marketed and pipeline drugs in Epoetin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Epoetin alfa: Overview
Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin. Epogen (epoetin alfa) injection for intravenous or subcutaneous administration is formulated as a sterile, clear, colorless liquid in vials in multiple formulations.
Epoetin alfa Biosimilars: Drugs Chapters
This segment of the Epoetin alfa report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, Phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Epoetin alfa Biosimilars: Marketed Drugs
Further product details are provided in the report……..
Epoetin alfa Biosimilars: Emerging Drugs
Further product details are provided in the report……..
Epoetin alfa: Therapeutic Assessment
This segment of the report provides insights about the different Epoetin alfa biosimilars segregated based on following parameters that define the scope of the report, such as:
Epoetin alfa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Epoetin alfa biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epoetin alfa biosimilar drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Epoetin alfa– Biosimilar 2022,” report provides comprehensive insights about 15+ companies and 20+ marketed and pipeline drugs in Epoetin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Epoetin alfa: Overview
Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin. Epogen (epoetin alfa) injection for intravenous or subcutaneous administration is formulated as a sterile, clear, colorless liquid in vials in multiple formulations.
Epoetin alfa Biosimilars: Drugs Chapters
This segment of the Epoetin alfa report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, Phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Epoetin alfa Biosimilars: Marketed Drugs
- Binocrit: Sandoz
- Epoimmun: Biosidus
Further product details are provided in the report……..
Epoetin alfa Biosimilars: Emerging Drugs
- UB 851: UBI Pharma
Further product details are provided in the report……..
Epoetin alfa: Therapeutic Assessment
This segment of the report provides insights about the different Epoetin alfa biosimilars segregated based on following parameters that define the scope of the report, such as:
- Major Players in Epoetin alfa
- Phases
- Marketed stage products
- Late stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II and
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Molecule Type
- Monoclonal antibodies
- Peptide
- Protein
- Small molecule
- Product Type
Epoetin alfa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Epoetin alfa biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epoetin alfa biosimilar drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Epoetin alfa R&D. The therapies under development are focused on novel approaches to treat/improve Epoetin alfa.
- In May 2018, Pfizer announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT (epoetin alfa-epbx), a biosimilar to Epogen and Procrit (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the US.
- In August 2018, Stada announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.
- Epoetin alfa Biosimilar Pipeline Analysis
- Therapeutic Assessment
- Sales Assessment
- Unmet Needs
- Impact of Drugs
- Marketed Product profiles
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Sales Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Epoetin alfa Biosimilars?
- How many Epoetin alfa biosimilars are developed by each company?
- How many emerging biosimilars are in mid-stage, and late-stage?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Epoetin alfa biosimilars therapeutics?
- What are the clinical studies going on for Epoetin alfa biosimilars and their status?
- What are the key designations that have been granted to the emerging drugs?
- Zydus Cadila
- Wockhardt
- UBI Pharma
- Sun Pharmaceutical Industires
- Stada Arzneimittel
- Sedico
- Sandoz
- Reliance Life Sciences
- Pfizer (Hospira)
- Duopharma
- Nanogen
- Medice Arzneimittel Pьtter
- LG Chem
- Hexal
- Emcure
- Dragon Pharmaceutical
- Claris Lifesciences
- Blau Farmaceutica
- Biosidus
- Biocon
- Biocad
- Apotex
- Amega Bitoech
- Johnson & Johnson
- PanGen
- EPO
- Wepox
- UB-851
- Ceriton
- Silapo
- Epoetin 2000 I.U.
- Binocrit
- Epostim
- ReliPoietin
- Retacrit
- Erisa (PDA10)
- Nanokine
- Abseamed
- Espogen
- Epoetin alfa Hexal
- Epofer
- BR 05001
- Epotin
- Eritromax
- Epoimmun
- Erypro
- Erythropoietin alfa biosimilar
- APO-EPO
- Recombinant erythropoietin
- Epoetin alfa - ProLease
- PDA 10
1. KEY INSIGHTS
2. EPOETIN ALFA BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. EPOETIN ALFA (REFERENCE PRODUCT: EPOGEN)
5.1. Product Overview
5.2. Indications
5.3. Mechanism of Action
5.4. Dosage and Administration
5.5. Dosage and Strengths
5.6. Dose Modification
5.7. Route of Synthesis
5.8. Pharmacology
5.9. Pharmacodynamics
5.10. Pharmacokinetics
5.11. Adverse Reactions
5.12. Product Snapshot
5.13. Development Milestones
6. REGULATORY MILESTONES
6.1. Approvals
6.2. Research and Development
6.3. Clinical Trials Information
6.4. Safety and Efficacy
7. EPOGEN BIOSIMILAR: EMERGING OPPORTUNITIES
8. EPOETIN ALFA: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. EPOETIN ALFA BIOSIMILARS PROFILES: BY COMPANY
9.1.1. PanGen Biotech
9.1.1.1. Erisa (PDA10): PanGen Biotech/Duopharma
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Reliance Life Sciences
9.1.2.1. Epostim: Reliance Life Sciences
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
9.1.2.2. ReliPoietin: Reliance Life Sciences
9.1.2.2.1. Product Information
9.1.2.2.2. Research and Development
9.1.2.2.3. Other Development Activities
9.1.2.2.4. General Description Table
*More Companies and products would be added in the final report
10. EPOETIN ALFA BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. EPOETIN ALFA BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
2. EPOETIN ALFA BIOSIMILARS: SNAPSHOT
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. REGULATORY OUTLOOK FOR BIOSIMILARS
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. EPOETIN ALFA (REFERENCE PRODUCT: EPOGEN)
5.1. Product Overview
5.2. Indications
5.3. Mechanism of Action
5.4. Dosage and Administration
5.5. Dosage and Strengths
5.6. Dose Modification
5.7. Route of Synthesis
5.8. Pharmacology
5.9. Pharmacodynamics
5.10. Pharmacokinetics
5.11. Adverse Reactions
5.12. Product Snapshot
5.13. Development Milestones
6. REGULATORY MILESTONES
6.1. Approvals
6.2. Research and Development
6.3. Clinical Trials Information
6.4. Safety and Efficacy
7. EPOGEN BIOSIMILAR: EMERGING OPPORTUNITIES
8. EPOETIN ALFA: BIOSIMILARS ASSESSMENT
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. EPOETIN ALFA BIOSIMILARS PROFILES: BY COMPANY
9.1.1. PanGen Biotech
9.1.1.1. Erisa (PDA10): PanGen Biotech/Duopharma
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Reliance Life Sciences
9.1.2.1. Epostim: Reliance Life Sciences
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
9.1.2.2. ReliPoietin: Reliance Life Sciences
9.1.2.2.1. Product Information
9.1.2.2.2. Research and Development
9.1.2.2.3. Other Development Activities
9.1.2.2.4. General Description Table
*More Companies and products would be added in the final report
10. EPOETIN ALFA BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY
11. EPOETIN ALFA BIOSIMILARS: COMPETITIVE LANDSCAPE
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report
12. MARKET DRIVERS
13. MARKET BARRIERS
14. SWOT ANALYSIS
15. APPENDIX
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research
16. BIBLIOGRAPHY
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT